Stereotactic Radiosurgery’s Post

📃Scientific paper: Teprotumumab in advanced reactivated thyroid eye disease Abstract: PURPOSE: To report the case of a patient with reactivated, refractory thyroid eye disease (TED) treated with teprotumumab. OBSERVATIONS: A 51-year-old female with a 16-year history of thyroid eye disease previously treated with orbital decompression and multiple eyelid surgeries presented in a recurrent flare of the disease. The disease recurrence was refractory to intravenous steroid therapy and only partially responsive to oral steroid therapy, and the patient developed dysthyroid optic neuropathy in the right eye with decreased visual acuity and color vision. Clinical activity score was 8/10 and proptosis measurements were 27 mm OD and 26 mm OS. The patient underwent treatment with eight infusions of teprotumumab coinciding with a low taper of oral prednisone and experienced resolution of dysthyroid optic neuropathy, decrease of clinical activity score to 1, and dramatic improvement in proptosis (17 mm OD, 17 mm OS) and extraocular muscle size on imaging. Thirty weeks after completion of teprotumumab and 2 weeks after the second dose of the COVID vaccine, she experienced another flare and subsequently underwent bilateral orbital decompressions. CONCLUSION: This case report suggests teprotumumab may be used in patients with reactivation of longstanding thyroid eye disease. Reduction of extraocular muscle size and improvement in proptosis suggest teprotumumab may be disease-modifying even in advanced cases. Continued on ES/IODE ➡️ https://etcse.fr/kf7i ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Teprotumumab in advanced reactivated thyroid eye disease Abstract: PURPOSE: To report the case of a patient with reactivated, refractory thyroid eye disease (TED) treated with teprotumumab. OBSERVATIONS: A 51-year-old female with a 16-year history of thyroid eye disease previously treated with orbital decompression and multiple eyelid surgeries presented in a recurrent flare of the disease. The disease recurrence was refractory to intravenous steroid therapy and only partially responsive to oral steroid therapy, and the patient developed dysthyroid optic neuropathy in the right eye with decreased visual acuity and color vision. Clinical activity score was 8/10 and proptosis measurements were 27 mm OD and 26 mm OS. The patient underwent treatment with eight infusions of teprotumumab coinciding with a low taper of oral prednisone and experienced resolution of dysthyroid optic neuropathy, decrease of clinical activity score to 1, and dramatic improvement in proptosis (17 mm OD, 17 mm OS) and extraocular muscle size on imaging. Thirty weeks after completion of teprotumumab and 2 weeks after the second dose of the COVID vaccine, she experienced another flare and subsequently underwent bilateral orbital decompressions. CONCLUSION: This case report suggests teprotumumab may be used in patients with reactivation of longstanding thyroid eye disease. Reduction of extraocular muscle size and improvement in proptosis suggest teprotumumab may be disease-modifying even in advanced cases. Continued on ES/IODE ➡️ https://etcse.fr/kf7i ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Redefining Rural Healthcare: Penn Trafford Family Medicine Pioneer Leads in Skin Cancer Detection with DermaSensor!   Kevin Wong, MD stated, “This is a rare quadruple win in medicine! It’s a win for the patients, a win for the providers, a win for dermatologists, and a win for insurers. For the patients, it may provide peace of mind with an adjunctive medical device for detecting all three common skin cancers. For the providers, DermaSensor generates an immediate, objective assessment of suspicious skin lesions for timely referrals. For dermatologists, DermaSensor helps prioritize patients requiring a higher level of care and more immediate attention. And for the insurers, this can result in prompt evaluation and treatment if malignancy is detected.” Read more https://lnkd.in/dBRdcYQi

Keto, with the proper ratio of o3/o6 is a great way to fight cancer. However, at baseline you need to know this: You body has two ways to kill cancer. A process called autophaghy and a protein called P53. When you are in a FED state (eating and five hours post eating) you turn both of these process OFF. When you are in a FASTED state (five hours past your last meal) you turn them ON. Eating breakfast, lunch, and dinner, as suggested by our USDA, will NOT allow a cancer patient to get much help from their own bodies at fighting the cancer. Intermittent fasting WILL ALLOW the body to assist in the fight against cancer. Eating in a window (start eating at noon and stop by 6,7,8p) and NOT eating outside that window is a great strategy for cancer patients to put their bodies into a healing state.

Glioblastoma (GBM) is a highly aggressive brain tumor with a median survival rate of 12 to 15 months under standard care, which includes surgery, radiation, and chemotherapy. The most common form of brain cancer in adults, GBM is challenging to treat due to its complex genetic makeup and the difficult environment it creates within the body. Despite aggressive treatment, fewer than 5% of patients survive beyond three years. A recent case report documented the three-year experience of a 64-year-old female patient diagnosed with GBM who undertook intensive ketogenic metabolic therapy (KMT) as an adjunct to standard treatment protocols. KMT involved prolonged fasting, time-restricted eating, and a modified ketogenic diet to lower the glucose ketone index (GKI) and target cancer cells' metabolic weaknesses. After commencing KMT, the patient maintained an average GKI of 1.65 in the first year and 2.02 in the second year. She achieved tumor stability, with no progression on imaging. She also experienced a decrease in chronic pain, an improved sense of well-being, and a healthy reduction in BMI from 28 to 20.5. In the third year, after the death of a family member, dramatically increased stress, and slightly reduced adherence to KMT resulting in a higher average GKI of 3.2, signs of cancer progression reappeared. Further treatments were initiated, but the patient's condition declined. She passed away in the 38th month after diagnosis. This case suggests that integrating KMT with standard GBM treatments may help maintain tumor stability and improve quality of life. Adherence to KMT was linked to positive outcomes, while relaxation of the diet coincided with disease progression, suggesting that a consistently low GKI may be key to KMT's effectiveness. Further research is needed to confirm these findings. — Phillips MCL, Thotathil Z, Dass PH, Ziad F, Moon BG. Ketogenic metabolic therapy in conjunction with standard treatment for glioblastoma: a case report. Oncol Let. 2024 Mar 26;27(5):230. doi: 10.3892/ol.2024.14363. 📌 Link to study: https://lnkd.in/gB9g9Q7x 📌 Find more research summaries on our website: https://lnkd.in/gKeXEcEN #Keto #Ketogenicdiet #Glioblastoma #Research

Hepatectomy: A Vital Procedure Against Liver Tumors Hepatectomy, a crucial surgical intervention, removes portions of the diseased liver, saving human lives by treating various liver disorders This surgical procedure involves partial or complete resection of the liver, depending on the severity and extent of the disease. Its primary purpose is to treat benign and malignant liver tumors, providing a valid therapeutic solution. When

#ophthalmology #uveitis #retina #acute_retinal_necrosis #ARN #herpesviruses #infection #inflammation #retinaldetachment #diagnosis #treatment #vision #review #update ✅ Check out our latest 📰 on Acute Retinal Necrosis (ARN) 👁 📖 ARN is a rare but severe ophthalmic pathology defined by panuveitis, retinal necrosis, and high rates of retinal detachment. It may lead to poor visual outcomes even if promptly diagnosed and treated. Despite significant progress in diagnosing and treating ARN, further research is needed to improve visual outcomes in this challenging clinical condition.

Did You Know? 🌟 Our Team's Contribution to the Latest European Thyroid Association Guidelines! We're proud to announce that our group´s role in developing the most recent European Thyroid Association guidelines for managing thyroid nodules. 📚✨ With the increasing detection of thyroid nodules thanks to advanced imaging technologies, our work focuses on providing a comprehensive guide for the initial evaluation and management of these nodules in adults, emphasizing cost-effectiveness and patient-centered approaches. 🏥🔍 It's important to note, these guidelines are specifically designed for thyroid nodules management and do not cover thyroid malignancy treatment. By integrating the latest research with our expert panel's clinical experience, we aim to refine and update practices for handling this common condition, respecting the patients' preferences every step of the way. 🩺💡 #endocrine #cytology #thyroidnodulemanagement #ETAguidelines #thyroid https://lnkd.in/eDTxi3sF 2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule https://lnkd.in/eek9bbqH • 2 min read

Are sporadic colorectal cancers in young patients distinct from those in elderly patients? Aim: To compare clinicopathological and oncological characteristics of sporadic colorectal cancer (CRC) between young (≤40 years) and elderly (≥70 years) patients without hereditary CRC mutations. Methodology: Cross-sectional, retrospective study of 1599 CRC patients who underwent surgery from January 2010 to December 2017 at 3 tertiary hospitals, including 157 young and 1442 elderly patients. Clinicopathological and oncological outcomes were compared. Main Result: No significant differences in tumour stage, location, or molecular features between groups. Young patients had better 3-year overall survival (97.4% vs. 83.5%) (but similar cancer-specific survival) Conclusion: Genetically proven sporadic CRCs in young and elderly patients are similar in tumour stage, location, and molecular features. Limitations: 1. Selection bias due to retrospective design. 2. Exclusion of hereditary CRC, family history, or IBD. 3. Unexplained lack of pathological differences. 4. Missing genetic test data due to financial issues/ insurance. 5. Small sample size in young CRC group, increasing risk of type 2 error. https://lnkd.in/gw8yQVta

ICYMI: Cornea Update: Persistent and Severe Mpox Keratitis Despite Systemic and Topical Treatment: Purpose: The purpose of this study was to report a case of peripheral ulcerative keratitis in a patient diagnosed with corneal polymerase chain reaction (PCR) and a positive mpox culture. Methods: This is a case report. Results: An immunocompetent 54-year-old man was diagnosed with conjunctivitis in his left eye 15 days after being diagnosed with mucocutaneous monkeypox. He received treatment with dexamethasone 0.1% and tobramycin 0.3% eye drops for 2 weeks. Two weeks after discontinuing this treatment, he developed peripheral ulcerative keratitis and a paracentral epithelial defect. Mpox keratitis was diagnosed by corneal culture and PCR. Corneal inflammation persisted for more than 6 months, manifested as corneal epithelial defect, limbitis, endotheliitis, neurotrophic changes, and trabeculitis. This persistence was observed alongside positive corneal PCR results, despite undergoing 2 courses of trifluorothymidine, 2 courses of oral tecovirimat, and intravenous cidofovir. An amniotic membrane transplantation was then performed. Conclusions: Persistent corneal pain and replication are possible with the mpox virus, even in immunocompetent patients. Having received treatment with topical corticosteroids before antiviral treatment for the pox virus may have contributed to the severity and persistence of the clinical condition. Cycle threshold PCR values can be used to support the diagnosis and monitor treatment effectiveness. http://dlvr.it/T49Z6w #Cornea #Ophthalmology #Ophthotwitter